BMI Department Seminar with Yeonhee Park, University of Wisconsin-Madison
Data-driven monitoring for phase II clinical trial designs based on percentile event time test
Friday, October 20, 2023
The goal of phase II clinical trials is to evaluate the therapeutic efficacy of a new drug. Some use the time-to-event endpoint as the primary endpoint of the phase II study to see the improvement of the therapeutic efficacy of a new drug in median survival time. Dr. Park will discuss a method that generalizes median event time test (METT) to any percentile of the survival time using a percentile event time test (PETT), and development of data-driven monitoring for phase II clinical trials.